308 related articles for article (PubMed ID: 36441502)
1. Treating Biliary Tract Cancers: New Targets and Therapies.
Ho J; Fiocco C; Spencer K
Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
3. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
Demols A; Bucalau AM; Mans L
Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
[TBL] [Abstract][Full Text] [Related]
4. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract][Full Text] [Related]
5. Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
Marin JJG; Prete MG; Lamarca A; Tavolari S; Landa-Magdalena A; Brandi G; Segatto O; Vogel A; Macias RIR; Rodrigues PM; Casta A; Mertens J; Rodrigues CMP; Fernandez-Barrena MG; Da Silva Ruivo A; Marzioni M; Mentrasti G; Acedo P; Munoz-Garrido P; Cardinale V; Banales JM; Valle JW; Bridgewater J; Braconi C;
Br J Cancer; 2020 Sep; 123(7):1047-1059. PubMed ID: 32694694
[TBL] [Abstract][Full Text] [Related]
6. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
Chakrabarti S; Kamgar M; Mahipal A
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722188
[TBL] [Abstract][Full Text] [Related]
8. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
10. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
Iyer P; Chen MH; Goyal L; Denlinger CS
Chin Clin Oncol; 2020 Feb; 9(1):7. PubMed ID: 32146818
[TBL] [Abstract][Full Text] [Related]
11. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
12. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
15. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
Zhu AX; Hezel AF
Hepatology; 2011 Feb; 53(2):695-704. PubMed ID: 21274890
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
17. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
18. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
19. Molecular-driven treatment for biliary tract cancer: the promising turning point.
Persano M; Puzzoni M; Ziranu P; Pusceddu V; Lai E; Pretta A; Donisi C; Pinna G; Spanu D; Cimbro E; Parrino A; Liscia N; Mariani S; Dubois M; Migliari M; Scartozzi M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1253-1264. PubMed ID: 34551663
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.
Lo JH; Agarwal R; Goff LW; Heumann TR
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
